Cilnidipine PCD Pharma Franchise Company

Cafoli Lifecare offers a Cilnidipine range of 23 tablet formulations, manufactured in WHO-GMP certified facilities. Distributors building a cardiac and antihypertensive portfolio can secure district-wise monopoly franchise rights on this fast-growing molecule.

What is Cilnidipine?

Cilnidipine is a fourth-generation dihydropyridine calcium channel blocker that inhibits both L-type and N-type calcium channels, lowering blood pressure while moderating sympathetic activity. Its dual action is associated with less reflex tachycardia and pedal oedema than conventional agents. Compound details are available on PubChem.

Therapeutic Applications

Cilnidipine is indicated for essential hypertension, alone or combined with other antihypertensives, and is often preferred in patients with amlodipine-induced ankle swelling or with proteinuria where N-type channel blockade may support renal protection. Prescribers include cardiologists, consultant physicians, nephrologists and general practitioners.

Why Cilnidipine is a High-Potential Molecule for Distributors

Hypertension therapy is lifelong, so every converted prescription becomes a monthly repeat sale. Cilnidipine is among the fastest-growing calcium channel blockers in India because it offers a clinically visible advantage — less pedal oedema — that makes switching from amlodipine easy to propose. With 23 strengths and combinations, partners can serve mono and combination therapy from a single WHO-GMP source.

Why Choose Cafoli Lifecare

Cafoli Lifecare is a WHO-GMP compliant, DCGI-approved PCD pharma company with 1000+ franchise partners across India. Partners receive district-wise monopoly rights, promotional inputs including visual aids, MR bags and product cards, and consistent stock availability backed by quality-tested manufacturing.

References

1. PubChem: Cilnidipine
2. PubMed: Cilnidipine in hypertension